The World Bank, pharmaceutical policies, and health reforms in Latin America

International Journal of Health Services

Volumn 35, Issue 4, 2005, Pages 691-717

  Homedes, Núria ^a   Ugalde, Antonio ^a   Forns, Joan Rovira ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

HEALTH CARE; PHARMACEUTICAL INDUSTRY; SOCIAL POLICY; WELFARE REFORM; WORLD BANK;

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DOCUMENTATION; FINANCIAL MANAGEMENT; POLICY; PURCHASING; REVIEW; SOUTH AND CENTRAL AMERICA;

DRUG COSTS; DRUG INDUSTRY; DRUGS, GENERIC; EFFICIENCY, ORGANIZATIONAL; FINANCIAL SUPPORT; HEALTH CARE REFORM; HUMANS; LATIN AMERICA; ORGANIZATIONAL OBJECTIVES; ORGANIZATIONAL POLICY; PHARMACEUTICAL PREPARATIONS; UNITED NATIONS;

EID: 27844562146     PISSN: 00207314     EISSN: 15414469     Source Type: Journal    
DOI: 10.2190/8F8L-0564-T9EN-EMP0     Document Type: Review

References (109)

1. IMS. Lipitor leads the way in 2003. www.ims-global.com//insight/ news_story/0403/news_story_040316.htm (June 5, 2004).
2. Pan American Health Organization. Health in the Americas, Vol. 2. Washington, D.C., 2002.
3. Rathe, M. Salud y equidad: Una mirada al financiamiento de la salud en la República Doninicana. Partnerships for Health Reform, Calverton, Md., 2000.
4. Vargas, N., and López-Linares, R. Acceso a medicamentos y uso racional de medicamentos. Unpublished document, 2001.
5. World Health Organization. The Public and Private Circuits for the Distribution of Drugs in the Chilean System. WHO Action Programme on Essential Drugs, Geneva, 1999.
6. Homedes, N., and Ugalde, A. Improving the use of pharmaceuticals through patient and community level interventions. Soc. Sci. Med. 52(1): 99-134, 2001.
7. Cohen, J. C. Public Policies in the Pharmaceutical Sector: A Case Study in Brazil. LCSSHD Paper Series no. 54. World Bank, Washington, D.C., 2000.
8. World Health Organization. Progress of WHO Member States in Developing National Drug Policies and in Revising Essential Drug Lists. WHO/DAP/98.7. WHO Action Programme on Essential Drugs, Geneva, 1998.
9. Multicenter study on self-medication in six Lain American countries. Clin. Pharmacol. Ther. 61: 488-493, 1997.
10. Van der Stuyft, P., Delgado, E., and Sorensen S. C. Utilisation rates and expenditure for public and private curative care services in semi-urban Guatemala. Ann. Trop. Med. Parasitol. 91: 209-216, 1997.
11. Medici, A. O SUS e a Política Hood Robin de Saúde. Mimeo. Inter-American Development Bank, Washington, D.C., 1998.
12. Pan American Health Organization. National Health Expenditure Financing. Washington, D.C., 1995.
13. Tobar, F. Acceso a medicamentos en Argentina: Diagnóstico y alternativas. Fundación ISALUD, Buenos Aires, 2002.
14. Leyva-Flores, R., Mario Bronfman, P. M., and Erviti-Erice, J. Simulated clients in drugstores: Prescriptive behaviour of drugstore attendants. J. Soc. Adm. Pharm. 17(3): 151-158, 2000.
15. Ugalde, A. Where there is a doctor: Strategies to increase productivity at lower costs. The economics of rural health care in the Dominican Republic. Soc. Sci. Med. 19(4): 441-450, 1984.
16. World Bank. The World Development Report: Investing in Health. Washington, D.C., 1993.
17. Ugalde, A., and Jackson, J. T. The World Bank and international health policy. J. Int. Dev. 7(3): 525-541, 1995.
18. The World Bank cure for donor fatigue (editorial). Lancet 342(8863): 63-64, 1993.
19. Dukes, G., and Broun, D. Pharmaceutical Policies: Rationale and Design. Human Resources Development and Operations Policy Working Papers no. 35. World Bank, Washington, D.C., July 1994.
20. Saxenian, H. Getting the Most out of Pharmaceutical Expenditures. Human Resources Development and Operations Policy Working Papers. World Bank, Washington, D.C., September 1994.
21. Preker, A. S., Feachem, R. G. A., and Ferranti, D. Sector Strategy: Health, Nutrition and Population. World Bank, Washington, D.C., 1997.
22. Govindaraj, R., Reich, M. R., and Cohen, J. C. World Bank Pharmaceuticals Discussion Paper: Human Development Network. World Bank, Washington, D.C., September 2000.
23. Arango, J. I., Carlevaro, P., and Velázquez, G. The Public and Private Circuits of the Distribution of Drugs in the Chilean Health System. Health Economics and Drugs, DAP Series no. 2. World Health Organization, Geneva, 1996.
24. Ruíz, L. Personal communication, June 17, 2003.
25. Vacca, C. Uso racional de medicamentos. Boletín Fármacos 6(4): 95-99, 2003.
26. ESPICOM Business Intelligence. World Pharmaceutical Markets. Mexico, April 11, 2003. www.marketresearch.com/browse.asp?categoryid=89&SID= 82623842-290558694-364720004 (April 26, 2003).
27. Figueras, A., et al. Health needs, drug registration and control in less developed countries - the Peruvian case. Pharmacoepidemiol. Drug Safety 11(1): 63-64, 2002.
28. Congreso de la República. Proyecto de ley general de salud: Exposición de motivos, Julio 1997.
29. Lipcovich, P. La apuesta ganada por los genéricos. Página 12, Buenos Aires, January 15, 2003.
30. Phang Romero, C. Reforma del sector salud y la política farmacéutica en Perú. Cad de Saude Publica 18(4): 1121-1138, 2002.
31. Levi, G. C., and Vitória, M. A. A. Fighting against AIDS: The Brazilian experience. AIDS 16: 2373-2383, 2002.
32. Oxfam (U.K.). Drug Companies vs. Brazil: The Threat to Public Health. May 2001. www.oxfam.org.uk/what_we_do/issues/health/downloads/drugcomp_brazil.rtf (September 11, 2003).
33. Godoy Garraza, L., and Monsalvo, M. Estimación del ahorro generado por la elección de alternativas más económicas de un medicamento. Boletín Fármacos 6(1): 73-75, 2003.
34. Tobar, F. ¿Cuánto son usados los medicamentos por su nombre genérico en Argentina? Boletín Fármacos 6(4): 91-94, 2003.
35. Ugalde, A., and Cañás, M. Últimos intentos para frustrar la aprobación de la ley de genéricos en Argentina. Boletín Fármacos 5(4): 18-22, 2002.
36. Ávalos, R. A. Roche amenaza a la Caja Costarricense del Seguro Social por calidad. Boletín Fármacos 6(4): 108, 2003.
37. Cohen, J. C., and Carikeo Montoya, J. Using Technology to Fight Corruption in Pharmaceutical Purchasing: Lessons Learned from the Chilean Experience. Unpublished document. World Bank, Washington, D.C., February 2001.
38. World Bank. HIV/AIDS Medicines and Related Supplies: Contemporary Context and Procurement. Technical guide. Washington, D.C., February 2004.
39. Rovira, J. Trade agreements, intellectual property, and the role of the World Bank in improving access to medicines in developing countries. Yale J. Health Policy Law Ethics 4(2): 101-112, 2004.
40. Autoridades renuncian ante escándalo de medicamentos vencidos. ABC, Asunción, Paraguay, October 1, 2002.
41. Figueras, A., and Laporte, J. R. Regulatory decisions in a globalised world - The domino effect of phenylpropanolamine withdrawal in LA. Drug Safety 25(10): 689-693, 2002.
42. Cañás, M., et al. Medicamentos nuevos del mercado: Relación valor intrínseco consumo-gasto. Paper presented at the eighth meeting of Grupo Argentino para el Uso Racional de Medicamentos, Mar del Plata, Argentina, September 16-18, 1999.
43. Cañás, M., et al. Medicamentos de riesgo inaceptable presentes en el mercado Argentino. Paper presented at the tenth meeting of Grupo Argentino para el Uso Racional de Medicamentos, Mar del Plata, Argentina, December 7-8, 2001.
44. Comparación de indicaciones de algunas especialidades farmacéuticas que contienen AINE como principios autorizados en el Perú, EE.UU. y Reino Unido. AIS-Peru 1(1): 1-4, 2000.
45. BUKO Pharma-Kampagne. Medicamentos alemanes: racionalidad terapéutica cuestionable. Unpublished report.
46. Pan American Health Organization. Health in the Americas, Vol. 1. Washington, D.C., 1998.
47. Kroeger, A., et al. Inadequate drug advice in the pharmacies of Guatemala and Mexico: The scale of the problem and explanatory factors. Ann. Trop. Med. Parasitol. 95(6): 605-616, 2001.
48. Dosmobian, D. Venta de medicamentos falsificados en Lima. Boletín Fármacos 5(2): 34, 2002.
49. Calleja, J. M., consultant for the European Union assigned to the Dominican Republic. Personal communication, March 15, 1999.
50. Valsecia, M., et al. Prescripción de medicamentos en pediatría en la Seguridad Social del Nordeste de Argentina. Boletín Fármacos 4(1): 19-22, 2001.
51. Reyes, H., et al. Factores asociados a incumplimiento terapéutico y costo del desperdicio de antimicrobianos en infección respiratoria alta y diarrea aguda. Boletín Fármacos 1(1): 10-13, 1998.
52. Pérez-Cuevas, R., et al. Improving physician prescribing patterns to treat rhinopharyngitis: Intervention strategies in two health systems of Mexico. So. Sci. Med. 42(8): 1185-1194, 1996.
53. Sánchez-Pérez, H. J., et al. Uso de medicamentos el la Región Fraylesca de Chiapas, México: Quiénes sí y quiénes no? Gac. Sanit. 10(56, suppl. 2): 35, 1996.
54. Paredes, P., et al. Factors influencing physicians' prescribing behavior in the treatment of childhood diarrhoea: Knowledge may not be the clue. Soc. Sci. Med. 42: 1141-1153, 1996.
55. Zarate, C. E., and Osenrich, J. L. Prescribing habits of Peruvian physicians and factors influencing them. Bull. Pan Am. Health Organ. 29: 328-355, 1995.
56. Calva, J., and Bohalil, R. Antibiotic use in a periurban community in Mexico: A household and drugstore survey. Soc. Sci. Med. 42(8): 1121-1128, 1994.
57. Gutiérrez, G., et al. Changing physician prescribing patterns: Evaluation of an educational strategy for acute diarrhea in Mexico City. Med. Care 32: 436-446, 1994.
58. Hogerzeil, H. V., et al. Field tests for rational drug use in twelve developing countries. Lancet 342: 1408-1410, 1993.
59. Homedes, N., and Ugalde, A. Patients' compliance with medical treatments in the third world: What do we know? Health Policy Plann. 8: 291-314, 1993.
60. Vicencio, D., Alfaro, A., and Martínez, J. L. Caracterí sticas de la adquisición de medicamentos en Morelia. Salud Pública Mex. 34: 554-561, 1992.
61. Ugalde, A., and Homedes, N. Estudio de consulta externa en Costa Rica. Development Technologies, San José, Costa Rica, 1988.
62. República de Colombia, Ministerio de la Protección Social, Pan American Health Organization. Medición de indicadores de política farmacéutica. Bogota, 2003.
63. Giraldo, J. C. Defensoría del Pueblo: Estimación de la satisfacción de los usuarios en la entrega de medicamentos. Bogota, 2000.
64. Vacca, C., and López, J., Secretaría distrital de salud de Bogotá, Hospital San Cristóbal. Evaluación de la información sobre terapia farmacológica dada al paciente ambulatorio en el hospital San Cristóbal. Revista de Ciencias Farmacéuticas (Colombia) 28: 1-6, 1999.
65. Vacca, C., Orozco, J., and Holguín, E. Equidad en el acceso y calidad de la terapia farmacológica en el marco de la Ley 100 de Seguridad Social en Colombia. Pan American Health Organization, Bogota, 2002.
66. Leyva, R. F., et al. Medical drug utilization patterns for febrile patients in rural areas of Mexico. J. Clin. Epidemiol. 50: 329-355, 1997.
67. El Comercio. Persiste el uso inadecuado de medicinas. Quito, March 10, 2003.
68. Asociación Nacional de Industriales. Estudio sobre automedicación y autoprescripción en América Latina. ILAR-ANDI, Bogota, 2003.
69. García, P. J., et al. Syndromic management of STDs in pharmacies: Evaluation and randomised intervention trial. Sex. Transm. Infect. 74: S153-S158, 1998.
70. Vacca, C., et al. La evaluación de la calidad de la entrega de medicamentos en droguerías de Bogotá. Fhasten Ltda, Secretaría Distrital de Salud de Bogotá, 2001.
71. Wazana, A. Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA 283(3): 373-380, 2000.
72. Angell, M. The pharmaceutical industry - to whom is it accountable? N. Engl. J. Med. 342(25): 1902-1904, 2000.
73. Estado de Minas Gerais. Mayoría de las propagandas de remedios en Brasil son irregulares, dice Anvisa. Boletín Fármacos 6(4): 100, 2003.
74. La Nación (Argentina). Publicidad de medicamentos, bajo la lupa. Boletín Fármacos 6(4): 104, 2003.
75. Díaz del Valle, J. L. Aumentan litigios contra farmacéuticas. Boletín Fármacos 6(4): 106, 2003.
76. Díaz del Valle, J. L. IPS (Chile) cerró cerca de 200 sumarios pendientes contra laboratorios farmacéuticos. Boletín Fármacos 6(4): 100, 2003.
77. Lexchin, J., and Grootendorst, P. Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: A systematic review of the evidence. Int. J. Health Serv. 34(1): 101-122, 2004.
78. Lashman, K. Pharmaceuticals in the Third World: An Overview. Working Paper Series. World Bank, Washington, D.C., November 30, 1986.
79. Kaplan, W. A., et al. Is Local Production of Pharmaceuticals a Way to Improve Pharmaceutical Access in Developing and Transitional Countries? Setting a Research Agenda. Boston University, School of Public Health, June 23, 2003. www1/worldbank.org/hnp/hsd/documents/LOCALPRODUCTION.pdf.
80. Kaplan, W. A. Local Production of Pharmaceuticals and Vaccines. Paper presented at a conference organized by the World Bank, The Role of Generics and Local Industry in Attaining the Millennium Development Goals (MDGs) in Pharmaceuticals and Vaccines, Washington, D.C., June 24-25, 2003.
81. Barton, J. H. TRIPS and the global pharmaceutical market. Health Aff. 23(3): 146-159, 2004.
82. Carvallo Giadrosic, L. Corte suprema autoriza a todos los laboratorios a producir Viagra. Boletín Fármacos 6(2): 25-26, 2003.
83. Homedes, N., López-Linares, R., and Ugalde, A. The Production of Generics in Latin America. Paper presented at a conference organized by the World Bank, The Role of Generics and Local Industry in Attaining the Millennium Development Goals (MDGs) in Pharmaceuticals and Vaccines, Washington, June 24-25, 2003.
84. Grogg, P. Health-Cuba: Nearly 80 Percent of Medicines Produced Locally. InterPress Services, March 19, 2001. www.aegis.com/news.html (May 30, 2004).
85. Tancer, R. S. The pharmaceutical industry in Cuba. Clin. Ther. 17(4): 1-8, 1995.
86. Cavallone, E. Practical Issues in Creating and Maintaining Local Pharmaceutical Production in Developing Countries. Paper presented at a Workshop organized by the World Bank, Improving Access to Drugs in Developing Countries, Washington, D.C., June 2, 2003.
87. Gutiérrez Arriola, A. México dentro de las reformas a los sistemas de salud y de seguridad social de América Latina. Siglo XXI, Mexico F.D., 2002.
88. Ministerio de Salud Pública. Plan nacional de salud (1994-1999). San Salvador, October 1994.
89. Ministerio de Salud Pública. Documento Guía Para la reforma del sector salud en El Salvador. Grupo de Reforma del Sector Salud, San Salvador, January 1995.
90. Ministerio de Salud Pública. La reforma de salud en Colombia y el plan maestro de implementación. Informe final, Programa Universidad de Harvard. Bogota, 1996.
91. Ugalde, A., and Homedes, N. Venda de Serviços Públicos de Saúde: un estudo qualitativo. In Pesquisa Qualitativa de Serviços de Saúde, ed. M. L. Magalhães and F. J. Mercado. Ed. Vozes, Sao Paulo, 2004.
92. Olvera Santana, L. Análisis de la implementación de la descentralización de los servicios de salud en el estado de Baja California Sur 1996-2000. Master's thesis, Instituto Nacional de Salud Pública, Cuernavaca, Mexico, 2002.
93. Homedes, N., and Ugalde, A. The Decentralization of the Health Secretariats in Nuevo León and Tamaulipas. Unpublished paper.
94. Tono, T. La crisis de los hospitales en Colombia. Paper presented at the conference The Innovations in Health Financing, Mexico City, April 20-21, 2004. http://conferencias.salud.gob.mx/ingles/index_ingles.html (May 14, 2004).
95. Zamora, J. Descentralización en el Instituto Salvadoreño del Seguro Social (ISSS). Unpublished paper, 2001.
96. Falkenberg, T., and Tomson, G. The World Bank and pharmaceuticals. Health Policy Plann. 15(1): 52-58, 2000.
97. Sabaté, E., Balal, A., and Reich, M. Financial and Policy Audit of the World Bank's Pharmaceutical Lending: Background Study for the World Bank Pharmaceutical Discussion Paper. Human Development Network, World Bank, Washington, D.C., September 2000.
98. Tapalova, A., and Rovira, J. Review of the Pharmaceutical Lending by the World Bank for the FY 1991-2002. Draft. World Bank, Washington, D.C., July 10, 2003.
99. Colitt, R. Brazil probe reveals decade of corruption in health contracts. Financial Times, June 2, 2004.
100. World Health Organization. WHO Medicines Strategy: Framework for Action in Essential Drugs and Medicines Policy 2000-2003. Geneva, 2000.
101. World Health Organization. Operational Principles for Good Pharmaceutical Procurement. Geneva, 2000.
102. World Health Organization. Guidelines for Developing National Drug Policies. Geneva, 1998.
103. World Health Organization. The Use of Essential Drugs: Sixth Report of the Expert Committee. WHO Technical Report Series no. 850. Geneva, 1995.
104. Rich, B. Mortgaging the Earth: The World Bank, Environmental Impoverishment, and the Crisis of Development. Beacon Press, Boston, 1994.
105. Geyndt, W. D. Managing the Quality of Health Care in Developing Countries. Technical Paper no. 258. World Bank, Washington, D.C., 1995.
106. Broun, D. The Procurement of Pharmaceuticals in World Bank Projects. Human Capital Working Paper. World Bank, Washington, D.C., July 31, 1994.
107. Homedes, N., and Ugalde, A. Why neoliberal health reforms have failed in Latin America. Health Policy 71(1): 83-96, 2005.
108. Mason, E. S., and Asher, R. E. The World Bank since Bretton Woods. Brookings Institute, Washington, D.C., 1973.
109. Homedes, N., and Ugalde, A., Multisource drug policies in Latin America: Survey of 10 countries. Bull. World Health Organ. 83(1): 64-70, 2005.